Erectile dysfunction is also termed as impotence and it is characterized by incapability to build up or sustain a penile erection during sexual intercourse. An Erection of penis involves hydraulic effect resulting from entry and retention of blood into spongy bodies within penis. Sexual arousal is responsible for initiation of this process which is signalized by impulse mechanism from brain to penile nerves. The causes of erectile dysfunction involve side effects of drugs, Cavernosal disorders, Neurogenic disorders, Aging, Psychological causes, Multiple sclerosis and Diabetes, and Lifestyle modifications. Pin-point analysis of global erectile dysfunction drugs market focuses on various aspects of market such as, market trends, market drivers, restrains and opportunities. Competitive landscape section focuses on key leaders within global erectile dysfunction drugs market and their major growth strategies. Deep-dive assessment of segments identifies the potential segment which would act as guide to strategist.
The demand for erectile dysfunction therapeutics is highly increasing due to high incidence of chronic diseases including neurogenic disorders, hypertension, diabetes and psychological disorders. Additionally, increasing aged population, patient education and awareness are some of the factors which also fuel the growth of this market. Despite of increasing demand for erectile dysfunction drugs, this market is going to experience a decline in forecast period due to patent expiration of major brands. On contrary, it will provide the key opportunity for generic manufacturers to enter the market. Amongst erectile dysfunction drug users, there is high prevalence of sexually transmitted diseases (STDs) and it could restrain the growth of this market. Generic drugs are the promising opportunity for this market. Moreover, novel drug delivery techniques can also potentiate the market growth.
Global Erectile Dysfunction Drugs Market by Therapeutics
The global erectile dysfunction drugs market by therapeutics is segmented into two categories such as, existing drugs and pipeline drugs. Existing drugs includes the major drug brands namely, Viagra, Levitra/Staxyn, Cialis, Zydena, Helleva, Stendra/Spedra Avanafil and Mvix. Viagra was the blockbuster drug by Pfizer which has generated large revenue for the company. Levitra and Cialis are the major competitor for Viagra and these two brands has also captured a potential market share. Owing to the patent expiration of these major brands during forecast period, market is going to experience a decline in total revenue for erectile dysfunction drugs.
Global Erectile Dysfunction Drugs Market by Geography
Geographically, global erectile dysfunction drugs market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global erectile dysfunction drugs market and it is expected to show the same results during forecast period due to the presence of Cialis and Viagra in U.S. market. Patent expiration of these brands outside the U.S. markets, would increase the influx of generics with cheaper prices.
The key players within global erectile dysfunction drugs market include Pfizer, Bayer AG, Eli Lilly & Co., Dong-A Pharmaceutical Co. Ltd, Vivus, Inc., Meda Pharmaceuticals and Apricus Biosciences. Competitors are focusing on novel product manufacturing which will show faster onset of action with minimal side effects as compared to existing therapies. Due to patent expiration of major brands in near future, would increase the competition for generic drugs with cheaper prices.
High Level Analysis
The comprehensive analysis of global erectile dysfunction drugs market provides the overview of the market and its key concerns. Market dynamics covers market drivers, restrains and opportunities within global erectile dysfunction drugs market and helps to understand market behaviour in simple way. Market segmentation section is informative towards each segment and assist in identification of potential segment. Porter’s five forces analysis offers the advantage of determination of profitable market. Suppliers bargaining power for global erectile dysfunction drugs market is high due to patentability of major brands but it is expected to decline in near future due to patent expiration and introduction of comparatively cheaper generics into market. Even though, novel drug deliveries are under clinical and pre-clinical phase, this market is characterized by weak pipeline growth and hence, threat of substitute product is moderate. Patent expiration of major brands outside the U.S. market would increase the threat form generic manufacturers as new entrants. Industrial rivalry is less intense due to big players retaining the major revenue generating brands but in near future it would increase to high extent due to off patenting of these drugs and entry of generic manufacturers into market.
This report offers the following benefits in particular:
The global erectile dysfunction drugs market is segmented into three major categories such as, equipment, application and geography.
MARKET BY THERAPEUTICS
MARKET BY GEOGRAPHY